144 related articles for article (PubMed ID: 11260504)
1. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.
Schultz ES; Zhang Y; Knowles R; Tine J; Traversari C; Boon T; van der Bruggen P
Tissue Antigens; 2001 Feb; 57(2):103-9. PubMed ID: 11260504
[TBL] [Abstract][Full Text] [Related]
2. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
Luiten RM; Demotte N; Tine J; van der Bruggen P
Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
[TBL] [Abstract][Full Text] [Related]
3. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
5. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.
Bilsborough J; Panichelli C; Duffour MT; Warnier G; Lurquin C; Schultz ES; Thielemans K; Corthals J; Boon T; van der Bruggen P
Tissue Antigens; 2002 Jul; 60(1):16-24. PubMed ID: 12366779
[TBL] [Abstract][Full Text] [Related]
6. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.
Kobayashi T; Lonchay C; Colau D; Demotte N; Boon T; van der Bruggen P
Tissue Antigens; 2003 Nov; 62(5):426-32. PubMed ID: 14617050
[TBL] [Abstract][Full Text] [Related]
7. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
8. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
9. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
[TBL] [Abstract][Full Text] [Related]
10. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.
Luiten R; van der Bruggen P
Tissue Antigens; 2000 Feb; 55(2):149-52. PubMed ID: 10746786
[TBL] [Abstract][Full Text] [Related]
11. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
Traversari C; van der Bruggen P; Luescher IF; Lurquin C; Chomez P; Van Pel A; De Plaen E; Amar-Costesec A; Boon T
J Exp Med; 1992 Nov; 176(5):1453-7. PubMed ID: 1402688
[TBL] [Abstract][Full Text] [Related]
12. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
Schultz ES; Chapiro J; Lurquin C; Claverol S; Burlet-Schiltz O; Warnier G; Russo V; Morel S; Lévy F; Boon T; Van den Eynde BJ; van der Bruggen P
J Exp Med; 2002 Feb; 195(4):391-9. PubMed ID: 11854353
[TBL] [Abstract][Full Text] [Related]
13. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
[TBL] [Abstract][Full Text] [Related]
14. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells.
Vigneron N; Ooms A; Morel S; Ma W; Degiovanni G; Van den Eynde BJ
Tissue Antigens; 2005 Feb; 65(2):156-62. PubMed ID: 15713214
[TBL] [Abstract][Full Text] [Related]
15. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
[TBL] [Abstract][Full Text] [Related]
16. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
17. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345
[TBL] [Abstract][Full Text] [Related]
18. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
[TBL] [Abstract][Full Text] [Related]
19. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
[TBL] [Abstract][Full Text] [Related]
20. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]